BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 36095139)

  • 1. Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010-2019: A retrospective observational study based on national surveillance data.
    Kajihara T; Yahara K; Nagi M; Kitamura N; Hirabayashi A; Hosaka Y; Abe M; Miyazaki Y; Sugai M
    Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36095139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal susceptibility of Candida isolates at one institution.
    Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J
    Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APX001A
    Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and Antifungal Susceptibility of
    Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
    Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018).
    Arastehfar A; Yazdanpanah S; Bakhtiari M; Fang W; Pan W; Mahmoudi S; Pakshir K; Daneshnia F; Boekhout T; Ilkit M; Perlin DS; Zomorodian K; Zand F
    Med Mycol; 2021 May; 59(5):422-430. PubMed ID: 32692816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt.
    El-Mahallawy HA; Abdelfattah NE; Wassef MA; Abdel-Hamid RM
    Curr Microbiol; 2023 Oct; 80(11):362. PubMed ID: 37796322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Six Antifungal Susceptibilities of 11
    Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
    Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida tropicalis is the most prevalent yeast species causing candidemia in Algeria: the urgent need for antifungal stewardship and infection control measures.
    Megri Y; Arastehfar A; Boekhout T; Daneshnia F; Hörtnagl C; Sartori B; Hafez A; Pan W; Lass-Flörl C; Hamrioui B
    Antimicrob Resist Infect Control; 2020 Apr; 9(1):50. PubMed ID: 32264966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.
    Pfaller MA; Moet GJ; Messer SA; Jones RN; Castanheira M
    Antimicrob Agents Chemother; 2011 Feb; 55(2):561-6. PubMed ID: 21115790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
    Wang H; Xu YC; Hsueh PR
    Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal susceptibility trend and analysis of resistance mechanism for Candida species isolated from bloodstream at a Japanese university hospital.
    Sakagami T; Kawano T; Yamashita K; Yamada E; Fujino N; Kaeriyama M; Fukuda Y; Nomura N; Mitsuyama J; Suematsu H; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
    J Infect Chemother; 2019 Jan; 25(1):34-40. PubMed ID: 30401513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
    Chen YC; Kuo SF; Chen FJ; Lee CH
    Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance.
    Najafzadeh MJ; Shaban T; Zarrinfar H; Sedaghat A; Hosseinikargar N; Berenji F; Jalali M; Lackner M; James JE; Ilkit M; Lass-Flörl C
    Med Mycol; 2024 Mar; 62(4):. PubMed ID: 38521982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.